Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

  • Revenue in USD (TTM)24.17bn
  • Net income in USD5.66bn
  • Incorporated1933
  • Employees23.30k
  • Location
    Bristol-Myers Squibb Co430 E 29th St Fl 14NEW YORK 10016-8367United StatesUSA
  • Phone+1 (212) 546-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BMY:NYQ since
Celgene CorpDeal completed03 Jan 201903 Jan 2019Deal completed14.34%79.38bn
Data delayed at least 15 minutes, as of Dec 06 2019 23:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Gilead Sciences, Inc.22.37bn2.71bn84.87bn11.00k31.864.1220.683.792.112.0917.4716.270.36235.376.602,033,182.004.3623.085.2028.2279.6084.3712.0443.522.876.070.542517.01-15.2414.59-46.0612.1737.10--
Eli Lilly And Co22.64bn4.44bn114.87bn38.68k25.7633.9820.225.074.648.2123.543.520.54881.394.36585,421.4010.776.4814.889.0077.7874.0119.6211.690.882922.100.814787.087.361.2299.27-6.1722.522.80
AbbVie Inc32.87bn3.32bn128.63bn30.00k38.94--24.283.912.232.1822.17-5.560.52334.075.811,095,567.005.329.307.2112.1277.0177.2410.1718.821.049.451.2783.7616.0811.751.066.835.3817.54
Amgen, Inc.23.40bn8.07bn138.90bn21.50k17.9412.7513.815.9413.0313.0337.7518.330.36881.346.641,088,140.0012.729.9615.5611.4282.0581.1534.4832.602.5914.980.731640.323.934.923.9010.561.2722.94
Bristol-Myers Squibb Co24.17bn5.66bn140.53bn23.30k17.335.5321.855.813.463.4614.7710.830.53035.705.431,037,468.0012.4710.0516.0713.9270.8573.8723.5217.903.7219.210.584374.948.596.6127.4914.1912.112.71
Data as of Dec 06 2019. Currency figures normalised to Bristol-Myers Squibb Co's reporting currency: US Dollar USD

Institutional shareholders

36.35%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2019132.11m8.11%
Wellington Management Co. LLPas of 30 Sep 2019109.66m6.73%
BlackRock Fund Advisorsas of 30 Sep 201977.27m4.74%
SSgA Funds Management, Inc.as of 30 Sep 201968.61m4.21%
Dodge & Coxas of 30 Sep 201950.45m3.10%
Fidelity Management & Research Co.as of 30 Sep 201940.42m2.48%
Renaissance Technologies LLCas of 30 Sep 201932.76m2.00%
Columbia Management Investment Advisers LLCas of 30 Sep 201929.24m1.80%
Geode Capital Management LLCas of 30 Sep 201927.42m1.68%
JPMorgan Investment Management, Inc.as of 30 Sep 201924.45m1.50%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.